Not all immune-checkpoint inhibitors are created equal

Meta-analysis and systematic review of immune-related adverse events in cancer trials

B. El Osta, F. Hu, Ramses F Sadek, R. Chintalapally, Shou-Ching Tang

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Background Targeting immune checkpoints is a novel approach in cancer therapy. This strategy may trigger immune related adverse events (irAE). We hypothesize that the incidence of irAE will be greater in patients receiving immune checkpoint inhibitors (ICI) targeting only immune cells compared to those that also target tumor cells (PD-L1). In addition, we compared the specific irAE profile and overall response rate (ORR) for each ICI by target(s). Materials and methods We reviewed all ICI cancer clinical trials (90; 174 arms) that reported irAE and were published through MEDLINE. 114 arms from 73 trials were eligible for this meta-analysis (including 11,328 patients). We collected and compared arm-specific data including ICI target, number of patients with irAE of any grade, grade 3+ and grade 5, specific irAE, and ORR. The R package “meta” was used to conduct a meta-analysis to calculate and compare the percentage of patients with irAE and ORR. Results The incidence (% of patients) of any grade irAE per ICI target was reported for 40 arms (3418 patients) treated with ICI. Most arms (80%) and patients (53%) studied were on phase 1/2 clinical trials. Patients were treated for solid malignancy on 39 arms (97%), mainly melanoma (40%). Two arms included ICI combinations. The incidence of any grade irAE was higher in patients who received ICI targeting CTLA-4 (53.8%) than PD-1 (26.5%) and PD-L1 ICI (17.1%) (P < 0.001). Comparative specific irAE rates were calculated for each ICI target. Conclusions Our systematic review supported our mechanistic-driven hypothesis. We encourage investigators to report the incidence of irAE in future ICI combination trials.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume119
DOIs
StatePublished - Nov 1 2017

Fingerprint

Meta-Analysis
Neoplasms
Incidence
Clinical Trials, Phase I
MEDLINE
Melanoma
Research Personnel
Clinical Trials

Keywords

  • Checkpoint inhibitors
  • Clinical trials
  • Immune-related adverse events
  • Meta-analysis
  • Systematic review

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Not all immune-checkpoint inhibitors are created equal : Meta-analysis and systematic review of immune-related adverse events in cancer trials. / El Osta, B.; Hu, F.; Sadek, Ramses F; Chintalapally, R.; Tang, Shou-Ching.

In: Critical Reviews in Oncology/Hematology, Vol. 119, 01.11.2017, p. 1-12.

Research output: Contribution to journalReview article

@article{3ebf600863f64599a10befa73f47a549,
title = "Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials",
abstract = "Background Targeting immune checkpoints is a novel approach in cancer therapy. This strategy may trigger immune related adverse events (irAE). We hypothesize that the incidence of irAE will be greater in patients receiving immune checkpoint inhibitors (ICI) targeting only immune cells compared to those that also target tumor cells (PD-L1). In addition, we compared the specific irAE profile and overall response rate (ORR) for each ICI by target(s). Materials and methods We reviewed all ICI cancer clinical trials (90; 174 arms) that reported irAE and were published through MEDLINE. 114 arms from 73 trials were eligible for this meta-analysis (including 11,328 patients). We collected and compared arm-specific data including ICI target, number of patients with irAE of any grade, grade 3+ and grade 5, specific irAE, and ORR. The R package “meta” was used to conduct a meta-analysis to calculate and compare the percentage of patients with irAE and ORR. Results The incidence ({\%} of patients) of any grade irAE per ICI target was reported for 40 arms (3418 patients) treated with ICI. Most arms (80{\%}) and patients (53{\%}) studied were on phase 1/2 clinical trials. Patients were treated for solid malignancy on 39 arms (97{\%}), mainly melanoma (40{\%}). Two arms included ICI combinations. The incidence of any grade irAE was higher in patients who received ICI targeting CTLA-4 (53.8{\%}) than PD-1 (26.5{\%}) and PD-L1 ICI (17.1{\%}) (P < 0.001). Comparative specific irAE rates were calculated for each ICI target. Conclusions Our systematic review supported our mechanistic-driven hypothesis. We encourage investigators to report the incidence of irAE in future ICI combination trials.",
keywords = "Checkpoint inhibitors, Clinical trials, Immune-related adverse events, Meta-analysis, Systematic review",
author = "{El Osta}, B. and F. Hu and Sadek, {Ramses F} and R. Chintalapally and Shou-Ching Tang",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.critrevonc.2017.09.002",
language = "English (US)",
volume = "119",
pages = "1--12",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Not all immune-checkpoint inhibitors are created equal

T2 - Meta-analysis and systematic review of immune-related adverse events in cancer trials

AU - El Osta, B.

AU - Hu, F.

AU - Sadek, Ramses F

AU - Chintalapally, R.

AU - Tang, Shou-Ching

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background Targeting immune checkpoints is a novel approach in cancer therapy. This strategy may trigger immune related adverse events (irAE). We hypothesize that the incidence of irAE will be greater in patients receiving immune checkpoint inhibitors (ICI) targeting only immune cells compared to those that also target tumor cells (PD-L1). In addition, we compared the specific irAE profile and overall response rate (ORR) for each ICI by target(s). Materials and methods We reviewed all ICI cancer clinical trials (90; 174 arms) that reported irAE and were published through MEDLINE. 114 arms from 73 trials were eligible for this meta-analysis (including 11,328 patients). We collected and compared arm-specific data including ICI target, number of patients with irAE of any grade, grade 3+ and grade 5, specific irAE, and ORR. The R package “meta” was used to conduct a meta-analysis to calculate and compare the percentage of patients with irAE and ORR. Results The incidence (% of patients) of any grade irAE per ICI target was reported for 40 arms (3418 patients) treated with ICI. Most arms (80%) and patients (53%) studied were on phase 1/2 clinical trials. Patients were treated for solid malignancy on 39 arms (97%), mainly melanoma (40%). Two arms included ICI combinations. The incidence of any grade irAE was higher in patients who received ICI targeting CTLA-4 (53.8%) than PD-1 (26.5%) and PD-L1 ICI (17.1%) (P < 0.001). Comparative specific irAE rates were calculated for each ICI target. Conclusions Our systematic review supported our mechanistic-driven hypothesis. We encourage investigators to report the incidence of irAE in future ICI combination trials.

AB - Background Targeting immune checkpoints is a novel approach in cancer therapy. This strategy may trigger immune related adverse events (irAE). We hypothesize that the incidence of irAE will be greater in patients receiving immune checkpoint inhibitors (ICI) targeting only immune cells compared to those that also target tumor cells (PD-L1). In addition, we compared the specific irAE profile and overall response rate (ORR) for each ICI by target(s). Materials and methods We reviewed all ICI cancer clinical trials (90; 174 arms) that reported irAE and were published through MEDLINE. 114 arms from 73 trials were eligible for this meta-analysis (including 11,328 patients). We collected and compared arm-specific data including ICI target, number of patients with irAE of any grade, grade 3+ and grade 5, specific irAE, and ORR. The R package “meta” was used to conduct a meta-analysis to calculate and compare the percentage of patients with irAE and ORR. Results The incidence (% of patients) of any grade irAE per ICI target was reported for 40 arms (3418 patients) treated with ICI. Most arms (80%) and patients (53%) studied were on phase 1/2 clinical trials. Patients were treated for solid malignancy on 39 arms (97%), mainly melanoma (40%). Two arms included ICI combinations. The incidence of any grade irAE was higher in patients who received ICI targeting CTLA-4 (53.8%) than PD-1 (26.5%) and PD-L1 ICI (17.1%) (P < 0.001). Comparative specific irAE rates were calculated for each ICI target. Conclusions Our systematic review supported our mechanistic-driven hypothesis. We encourage investigators to report the incidence of irAE in future ICI combination trials.

KW - Checkpoint inhibitors

KW - Clinical trials

KW - Immune-related adverse events

KW - Meta-analysis

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85032727826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032727826&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.09.002

DO - 10.1016/j.critrevonc.2017.09.002

M3 - Review article

VL - 119

SP - 1

EP - 12

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -